Alterity Therapeutics Limited (NASDAQ:ATHE – Get Free Report) saw a large decline in short interest in the month of January. As of January 15th, there was short interest totalling 84,300 shares, a decline of 49.6% from the December 31st total of 167,300 shares. Based on an average daily trading volume, of 67,100 shares, the short-interest ratio is currently 1.3 days. Currently, 1.0% of the company’s shares are sold short.
Alterity Therapeutics Stock Performance
NASDAQ:ATHE traded up $0.23 during trading hours on Friday, reaching $4.80. The company’s stock had a trading volume of 791,484 shares, compared to its average volume of 80,638. The stock has a 50 day moving average price of $2.78 and a two-hundred day moving average price of $1.83. Alterity Therapeutics has a 12 month low of $1.00 and a 12 month high of $5.87.
Wall Street Analyst Weigh In
Separately, Maxim Group lifted their price objective on Alterity Therapeutics from $8.00 to $12.00 and gave the company a “buy” rating in a report on Thursday.
Institutional Investors Weigh In On Alterity Therapeutics
An institutional investor recently raised its position in Alterity Therapeutics stock. HB Wealth Management LLC grew its position in Alterity Therapeutics Limited (NASDAQ:ATHE – Free Report) by 34.1% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 31,883 shares of the company’s stock after buying an additional 8,100 shares during the period. HB Wealth Management LLC owned 0.44% of Alterity Therapeutics worth $110,000 at the end of the most recent quarter. 2.14% of the stock is owned by hedge funds and other institutional investors.
About Alterity Therapeutics
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia. The company’s lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson’s disease.
Featured Articles
- Five stocks we like better than Alterity Therapeutics
- How to Profit From Value Investing
- ServiceNow Stock Slips, But AI Expansion Signals Long-Term Gains
- 10 Best Airline Stocks to Buy
- Microsoft and Meta’s AI Investment Plans Are Full Steam Ahead
- What is the Shanghai Stock Exchange Composite Index?
- Beyond Self-Driving Cars: Factory Automation Takes Center Stage
Receive News & Ratings for Alterity Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alterity Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
